Ceritinib
Alectinib
Brigatinib
Trial
ASCEND-1
(Kim et al. Lancet Oncol 2016)
ASCEND-2
(Crino et al. J Clin Oncol 2016)
NP28761
(Shaw et al. Lancet Oncol 2016)
NP28673
(Ou et al. J Clin Oncol 2016)
Phase I/II
(Gettinger et al.
Lancet Oncol 2016)
ALTA
(180 mg arm)
(Kim et al. ASCO 2016)
N
163
140
67
122
71
110
RR
56 %
38.6 %
52.2 %
50.8 %
62 %
54 %
DCR
74 %
77 %
79.1 %
78.7 %
87 %
87 %
mPFS
6.9 m
5.7 m
8.1 m
8.9 m
12.9 m
12.9 m
CRIZOTINIB resistance
